医药魔方 / 最新资讯 / 正文

亚盛医药与UNITY Biotechnology达成授权许可协议

医药魔方 医药魔方 来源:医药魔方
2019-01-09
亚盛医药
原文

1月8日,亚盛医药宣布与合作伙伴UNITY Biotechnology (Nasdaq:UBX)达成协议。UNITY选择亚盛医药的一款在研化合物作为其眼科产品线的主要开发候选药物,将进一步开展临床前研究,以推进IND申请。此前双方已经达成关于化合物库的合作协议,UNITY获授权可对亚盛医药的Bcl-2系列化合物进行筛选,以用于在抗衰老领域的开发。目前双方已就选定的化合物UBX1967签订了许可协议。根据该许可协议条款,亚盛医药有权获得以UNITY普通股形式支付的预付款,以及按照UBX1967的临床开发和商业销售进展获得里程碑付款和销售分成。

 

“很高兴UNITY选择了我们的这一化合物用于与衰老相关的眼部疾病的新药研究,”亚盛医药董事长杨大俊博士表示,“这一举措也是对我们的进一步肯定,即亚盛医药在针对包括Bcl-2靶点在内的难以靶向的蛋白-蛋白相互作用小分子抑制剂研发领域的行业领先地位。”

 

关于亚盛医药

亚盛医药是一家立足中国、面向全球的处于临床阶段的原创新药研发企业,致力于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。亚盛医药研发产品管线主要专注细胞凋亡路径关键蛋白的抑制剂,通过抑制BCL-2、IAP或MDM2-p53等,重启肿瘤细胞的凋亡程序;第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂等。公司现有8个新药项目已进入到中国、美国及澳大利亚的I-II期临床开发阶段。

 

关于UNITY Biotechnology

UNITY Biotechnology致力于通过延缓、终止乃至逆转和衰老有关的疾病,从而延长人类的健康寿命。UNITY的研究主要集中在基于清除衰老细胞的抗衰老治疗药物开发。通过清除衰老细胞,可以治疗与衰老相关的疾病,例如骨关节炎、眼部疾病和肺部疾病等。


机器翻译

On January 8, Yasheng Pharmaceutical announced an agreement with partner UNITY Biotechnology (Nasdaq: UBX).UNITY selects a research compound from Yasheng Pharmaceutical as its main development candidate for its ophthalmic product line, and will further conduct preclinical research to advance IND applications.Previously, the two sides have reached a cooperation agreement on the compound library. UNITY is authorized to screen Yasheng Pharmaceutical's Bcl-2 series of compounds for development in the field of anti-aging.At present, both parties have signed a licensing agreement on the selected compound UBX 1967.Under the terms of the license agreement, Yasheng Pharmaceutical has the right to receive advance payments in the form of UNITY common shares, as well as milestone payments and sales share in accordance with UBX 1967 clinical development and commercial sales progress.

"I am glad that UNITY has selected our compound for new drug research in aging-related eye diseases," said Dr. Yang Dajun, chairman of Yasheng Pharmaceutical. "This initiative is also a further affirmation of us, that is, Yasheng Pharmaceutical's leading position in the field of research and development of difficult-to-target protein-protein interaction small molecule inhibitors, including Bcl-2 targets."

About Yasheng Pharmaceutical

Yasheng Pharmaceutical is a China-based, global-oriented, original and innovative drug research and development company dedicated to the development of innovative drugs in therapeutic areas such as cancer, hepatitis B, and aging-related diseases.The company has a self-developed protein-protein interaction targeted drug design platform.Yasheng Pharmaceutical's R & D product pipeline focuses on inhibitors of key proteins in the apoptosis pathway, restarting the apoptosis program of tumor cells by inhibiting BCL-2, IAP, or MDM2-p53, and second- and third-generation inhibitors of kinase mutants that appear in cancer therapy.The company's existing 8 new drug projects have entered Phase I-II clinical development in China, the United States and Australia.

About UNITY Biotechnology

UNITY Biotechnology is committed to extending the healthy lifespan of humans by delaying, terminating or even reversing diseases related to aging.UNITY's research focuses on the development of anti-aging therapeutics based on the removal of senescent cells.By eliminating senescent cells, aging-related diseases such as osteoarthritis, eye diseases, and lung diseases can be treated.

魔方微信公众号